Berkeley Lab startup Second Genome was highlighted in a KQED Science story about gut bacteria. Second Genome is in Phase 1 clinical trials for a drug to treat inflammatory bowel disease (IBD). For the complete story, go here.
Berkeley Lab startup Second Genome was highlighted in a KQED Science story about gut bacteria. Second Genome is in Phase 1 clinical trials for a drug to treat inflammatory bowel disease (IBD). For the complete story, go here.